Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
News|Articles|March 31, 2026
Q1 2026 recap: 6 FDA approvals pediatricians need to know
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Patrick Campbell, Yasmeen Qahwash
A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.
Advertisement
Advertisement
The first quarter of 2026 marked a period of profound advancement in pediatric health care, driven by a wave of FDA drug approvals that offer renewed hope for some of the most complex and rare pediatric conditions. From historic, first-of-their-kind systemic therapies for ultrarare disorders such as Menkes disease and Hunter syndrome to critical new interventions for achondroplasia and acquired hypothalamic
Related to this article
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.
Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
Advertisement
Advertisement